Abstract: A friction washer for a limited slip differential is provided, with the friction washer including a disk body having first and second opposing surfaces. The first and second opposing surfaces define respective first and second contact planes and include recesses that extend into the disk body from the respective first and second contact planes such that only a portion of the disk body extends to the respective first and second contact plane. The recesses are defined by partial spherical or partial cylindrical surfaces. This provides improved properties for holding lubricating fluid circulated within the differential so that the hydrodynamic pressure created between the friction surfaces provides a more consistent film or boundary layer of the lubricating fluid for a more uniform coefficient of friction over various operating speeds and pressures.

Abstract: Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

Abstract: The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha (EPAS1) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC.

Abstract: A differential for an e-axle that includes an oil collector for enhancing oil distribution to the differential. Unlike conventional differentials, a differential in accordance with the present disclosure is not submerged in fluid. Rather, the oil collector collects fluid sprayed by other transmission components (e.g., a ring gear) and directs the fluid to the differential.

Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.

Abstract: Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.

Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.

Abstract: Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

Abstract: The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha (EPAS1) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC.

Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.

Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.

Abstract: Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for ?v?3 integrin and/or ?v?5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin ?v?3, integrin ?v?5, or both integrin ?v?3 and integrin ?v?5. Compositions that include integrin targeting ligands and methods of use are also described.

Abstract: Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for ?v?3 integrin and/or ?v?5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin ?v?3, integrin ?v?5, or both integrin ?v?3 and integrin ?v?5. Compositions that include integrin targeting ligands and methods of use are also described.

Abstract: Synthetic av?6 integrin ligands of Formula I having serum stability and affinity for integrin av?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin av?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include avB6 integrin ligands and methods of use are also described.

Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.

Abstract: Transactional data accesses are performed in a data storage system, where the data storage system is configured to store a plurality of data objects identified by respective key values. A request is received to modify the value of a particular data object. The request specifies a modified object value and a key value identifying the data object to be modified. In response to the request, a transactional data object is created, the transactional data object specifying a transaction identifier, the original object value and the modified object value. The transactional data object is stored in the data storage system, and associated with the key value.

Abstract: Transactional data accesses are performed in a data storage system, where the data storage system is configured to store a plurality of data objects identified by respective key values. A request is received to modify the value of a particular data object. The request specifies a modified object value and a key value identifying the data object to be modified. In response to the request, a transactional data object is created, the transactional data object specifying a transaction identifier, the original object value and the modified object value. The transactional data object is stored in the data storage system, and associated with the key value.

Abstract: A system and method for processing a distributed transaction for an application are disclosed. Conventionally transactions on critical data (e.g. financial information) are processed using a database architecture whereby a persistent database (typically a redundant disk array) comprises the master record. In cases where large amounts of data need to be accessed but absolute data integrity is less critical, for example search engines, processing is conducted on live in-memory data without all the data being backed up, which can be much faster but data can be lost when processors fail. There have been attempts to use data grid architectures with some backup to persistent stores for more important data but these have either introduced disk access bottlenecks or required manual intervention in the event of failure.

Abstract: A system and method for processing a distributed transaction for an application are disclosed. Conventionally transactions on critical data (e.g. financial information) are processed using a database architecture whereby a persistent database (typically a redundant disk array) comprises the master record. In cases where large amounts of data need to be accessed but absolute data integrity is less critical, for example search engines, processing is conducted on live in-memory data without all the data being backed up, which can be much faster but data can be lost when processors fail. There have been attempts to use data grid architectures with some backup to persistent stores for more important data but these have either introduced disk access bottlenecks or required manual intervention in the event of failure.